Da Hee Han, PharmD

Most Recent Articles by Da Hee Han, PharmD

Canagliflozin May Improve Renal Outcomes in Patients With Type 2 Diabetes

Canagliflozin May Improve Renal Outcomes in Patients With Type 2 Diabetes

By

The renal protective benefit was seen in patients with both reduced (eGFR <60mL/min/1.73m2) and preserved (eGFR ≥60mL/min/1.73m2) renal function.

FDA Approves Unique Device for Diabetic Retinopathy Screening

FDA Approves Unique Device for Diabetic Retinopathy Screening

By

This is the first device authorized for marketing that provides a screening decision without the need for clinician interpretation.

FDA Puts New Restrictions on Permanent Birth Control Implant Essure

FDA Puts New Restrictions on Permanent Birth Control Implant Essure

By

The new Essure labeling restricts the sale and distribution of the device to only health care providers and facilities that provide information to patients about the risks and benefits of this device.

Bydureon Single Dose Trays to Be Discontinued

Bydureon Single Dose Trays to Be Discontinued

By

The Food and Drug Administration (FDA) has issued a discontinuation notice for Bydureon (exenatide extended-release; AstraZeneca) for injectable suspension Single Dose Trays.

Bydureon Approved for Use With Basal Insulin for Uncontrolled T2D

Bydureon Approved for Use With Basal Insulin for Uncontrolled T2D

By

The DURATION-7 study examined the effect of Bydureon or placebo as add-on therapy to insulin glargine, with or without metformin, in adults with T2D.

More Articles by Da Hee Han, PharmD

Sign Up for Free e-Newsletters

CME Focus